| Warning:  Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
 Deprecated:  str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
 
  
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 
 Warning:  Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
 Warning:  file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20138997&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
 in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
   English Wikipedia
 
 Nephropedia Template TP (
 
 Twit Text
 
 
 DeepDyve
 Pubget Overpricing
 | lüll   
 
 The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin,  relieves carrageenan-induced inflammation and hyperalgesia in mice Costa B; Bettoni I; Petrosino S; Comelli F; Giagnoni G; Di Marzo VPharmacol Res  2010[Jun]; 61 (6): 537-46Given that the pharmacological or genetic inactivation of fatty acid amide  hydrolase (FAAH) counteracts pain and inflammation, and on the basis of the  established involvement of transient receptor potential vanilloid type-1 (TRPV1)  channels in inflammatory pain, we tested the capability of a dual FAAH/TRPV1  blocker, N-arachidonoyl-serotonin (AA-5-HT), to relieve oedema and pain in a  model of acute inflammation, and compared its efficacy with that of a single FAAH  inhibitor (URB597) or TRPV1 antagonist (capsazepine). Acute inflammation was  induced by intraplantar injection of lambda-carrageenan into mice and the  anti-inflammatory and anti-nociceptive actions of AA-5-HT were assessed at  different doses, time points and treatment schedule. In addition, endocannabinoid  levels were measured in paw skin and spinal cord. Systemic administration of  AA-5-HT elicited dose-dependent anti-oedemigen and anti-nociceptive effects,  whereas it was devoid of efficacy when given locally. When tested in a  therapeutic regimen, the compound retained comparable anti-inflammatory effects.  TRPV1 receptor mediated the anti-inflammatory property of AA-5-HT, whereas both  CB(1) and TRPV1 receptors were involved in its anti-hyperalgesic activity. These  effects were accompanied by an increase of the levels of the endocannabinoid  anandamide (AEA) in both inflamed paw and spinal cord. AA-5-HT was more potent  than capsazepine as anti-oedemigen and anti-hyperalgesic drug, whereas it shows  an anti-oedemigen property similar to URB597, which was, however, devoid of the  anti-nociceptive effect. AA-5-HT did not induce unwanted effects on locomotion  and body temperature. In conclusion AA-5-HT has both anti-inflammatory and  anti-hyperalgesic properties and its employment offers advantages, in terms of  efficacy and lack of adverse effects, deriving from its dual activity.|Amidohydrolases/*antagonists & inhibitors[MESH]|Analgesics/*therapeutic use[MESH]|Animals[MESH]|Anti-Inflammatory Agents/*therapeutic use[MESH]|Arachidonic Acids/*therapeutic use[MESH]|Benzamides/therapeutic use[MESH]|Capsaicin/analogs & derivatives/therapeutic use[MESH]|Carbamates/therapeutic use[MESH]|Carrageenan[MESH]|Hyperalgesia/*drug therapy[MESH]|Inflammation/chemically induced/*drug therapy[MESH]|Mice[MESH]|Receptor, Cannabinoid, CB1/metabolism[MESH]|Serotonin/*analogs & derivatives/therapeutic use[MESH]|TRPV Cation Channels/*antagonists & inhibitors/metabolism[MESH]
 |